| Gene name | Expression Fold Change | Effect on lung cancer |
| ACTG1 | −66.515 | Found to be upregulated in small cell lung cancers. Overexpression has been linked to higher metastatic potential in hepatocellular carcinoma. This suggests that ACTG1 is likely assisting in cancer metastasis in lung cancers [14] . |
| ENO1 | −177.945 | Found to induce tumor growth and metastasis in vivo in lung adenocarcinomas [15] |
| FLNA | −67.865 | High expression induces resistance to gefitinib, while lowering expression restores sensitivity to gefitinib. Lower expression is also able to induce apoptosis [3] . |
| LARP4 | 25.148 | Typically has a lower expression in non-small cell lung cancers including A549. Higher expression could inhibit migration and invasion [4] . |
| RPL19 | −115.264 | Lowering RPL19 levels was found to inhibit the growth of lung cancers that typically have an overexpression of RPL19. It is a proposed target for immunotherapy [16] . |
| RPS16 | −73.909 | Higher levels linked to lower survival rate in lung cancer patients [17] . |
| RPS27A | −88.972 | Direct transcriptional target of p53 that is highly overexpressed in lung cancer. Appears to be a promising target for treatment [18] . |
| TM4SF1 | −86.345 | Upregulated in non-small cell lung cancers. Promotes cell proliferation, migration, and invasion while also inhibiting apoptosis [19] . |
| UBB | −84.321 | Overexpression leads to a lower survival rate in lung cancer patients [20] . |
| YBX1 | −75.424 | High levels have been associated with poor prognosis in cancer patients [21] . |